"As a big country, Indonesia must continue to increase its health (system) resilience," Deputy for Health Quality Improvement and Population Development Coordination at the Coordinating Ministry for Human Development and Culture, Agus Suprapto, stated when contacted here on Friday.
Suprapto remarked that in general, health system resilience could be described as the ability to face public health emergencies and non-natural disasters due to disease outbreaks, global pandemics, and so on.
"Health (system) resilience covers many aspects, right from public health to strengthening the health industry sector," he pointed out.
According to Suprapto, development of the SOE vaccine is part of the efforts to strengthen the health industry sector in the country, especially the vaccine industry.
"Thus, the community must be proud of the development of the SOE vaccine that has proved that the country's health industry is getting stronger," he remarked.
Suprapto also expressed optimism that the SOE vaccine can further strengthen Indonesia's sovereignty in supporting the improvement of the global health architecture.
"With the SOE vaccine, Indonesia can produce its own vaccine, with a large production capacity," he remarked.
The deputy also expressed optimism that the locally-made vaccine would contribute positively to increasing Indonesia's vaccination achievements, especially for booster dose vaccinations and children's vaccinations.
Earlier, on Thursday, June 9, 2022, state-run pharmaceutical firm PT Bio Farma had begun the phase three clinical trial of the SOE vaccine.
Director of Bio Farma Honesti Basyir affirmed that if the clinical trial goes well and receives an emergency use authorization, Bio Farma will start production of the vaccine in July 2022.
The third phase clinical trial of the SOEs vaccine involves as many as 4,050 subjects aged 18 to 70 years.
Bio Farma is planning to use the vaccine for booster vaccinations and children's vaccinations. (INE)
Close
EDITED BY INE
Translator: Wuryanti Puspitasari, Raka Adj
Editor: Agus Setiawan
Copyright © ANTARA 2022
